RxDoctor Payments Data

David Lessen, MD

Hematology & Oncology · Ft Lauderdale, FLNPI 1871518373

Payments from drug & device makers

$327,859in general payments, 2019–2025

Across 292 payments — averaging $1122.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$292K
  • Amgen$32K
  • Bristol Myers Squibb$2K
  • Bayer$900
  • Johnson & Johnson$565
  • Pfizer$189
  • plus $574 from 17 others

What the payments were for

  • Consulting fees$28,78014%
  • Speaking & faculty fees$149,67173%
  • Travel & lodging$23,81812%
  • Food & beverage$3,4292%
  • Education$3270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$327,859 in reported general payments places this provider in the 75th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$135,462
Medicare patients
266
Services billed
1,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib37$545,156
Imatinib Mesylate23$34,425
EliquisApixaban22$15,090
Acyclovir27$294
Allopurinol16$59
Warfarin Sodium13$51
Prednisone13$24
Folic Acid11$12

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$17$545,15637 claims
PfizerEliquis$189$15,09022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Ft Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →